Current reports March 15, 2021<\/p>\n\n\n\n
Date prepared: March 15, 2021 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering \u2013 current and periodical information<\/p>\n\n\n\n
Content of the report:
With reference to current report No. 9\/2021 of February 16, 2021, in which Celon Pharma S.A. (\u201cCompany\u201d) announced the adoption of resolution No. 4\/2021 of the Extraordinary General Meeting of Shareholders on amending of the Company’s Articles of Association and authorising the Company’s Management Board to increase the share capital within the authorized capital with the possibility for the Management Board to exclude the pre-emptive rights issued within the authorized capital in whole or in part with the consent of the Supervisory Board, the Management Board of the Company hereby announces that a resolution on the issue of not more than 15,000,000 series D ordinary bearer shares has been adopted as part of the above-mentioned increase of its authorized share capital. The Company encloses a copy of the adopted resolution.<\/p>\n\n\n\n
The resolution will enter into force subject to registration by the competent registry court of the amendments to the Company’s Articles of Association set out in Resolution No. 4\/2021 of the Extraordinary General Meeting of February 16, 2021.<\/p>\n","protected":false},"excerpt":{"rendered":"